Follow on

Predictive Antibody Screening- Cyrex Labs-What is it and Who should Get This Test

Price:  The Lymphocyte MAP Testing and Consult 

$895

The Lymphocyte MAP can:

  • Provide you with very useful surrogate markers for the diagnosis of autoimmune diseases, immune deficiencies, allergies and hypersensitivities.
  • Give you an invaluable picture of underlying immune imbalances that may trigger complex diseases.
  • Help you see how environmental triggers could affect your immune system, possibly resulting in a disease.
  • Help you identify immune conditions at an earlier stage, which if not addressed, may cause over-reaction (autoimmunity), or under-reaction (immune deficiencies) of the immune system, thus gauge existing susceptibilities.
  • Give you a more precise immune picture to help plan a treatment regimen or monitor its success.

The Lymphocyte MAP opens a new world for the immune system analysis and identifies important correlations with disease conditions.

The Lymphocyte MAP™, is an innovative new test which establishes a new standard in screening the immune system. It measures the integrity of the immune system at the cellular level to help identify a patient’s immune status and immunotype(s), based on 28 key biomarkers and determinants.

It utilizes an advanced proprietary flow cytometry method, which combines cutting-edge laser technology with monoclonal antibodies, to precisely measure the properties of living cells such as size, shape, density and granularity which results in a precise count of various lymphocyte subpopulations.

This helps identify patterns of imbalance of T cells, B cells and Natural Killer cells. It then organizes these patterns into specific immunotypes to provide an invaluable picture of the immune system.

The Lymphocyte MAP™

Exclusive immunophenotyping to help identify immune deficiency, immune over-activity, infections, inflammation, autoimmunities, allergies, asthma, hypersensitivities, and cancers

 

 

The Lymphocyte MAP™ – Numbers, Ratios, Percentages and Activity – NRPA

Lymphocytes and their subpopulations are the key elements of the immune system. In adults, they account for about 20-49% of the total number of white blood cells. It would be vitally important to measure decrease or increase in the percentage and number of these important lymphocytes. It is the numbers, ratios, percentages and activity level of these lymphocytes, and their subpopulations which are responsible for protection against various environmental factors, including viruses.

When healthy, these NRPAs are in a precise and pre-determined relationship to one-another. It is the disruption of these finely balanced relationships which can compromise the immune function.

These are NOT measured by a CBC test, which is just part of a yearly checkup. There is a significant difference between lymphocyte immunophenotyping and the complete blood count (CBC), which is used for checking the overall health of a patient.

A CBC could be absolutely normal, but the patient could actually be suffering from immune dysfunction, which includes immune deficiencies, hidden inflammation, autoimmunities, hypersensitivities and allergies induced by environmental triggers. These immune disorders can be detected by the advanced immunophenotyping of lymphocytes done by Cyrex Labs.

Key Features of The Lymphocyte MAP

  1. Thirteen immunotypes uniquely designed to capture and highlight important immune trends revealed due to the comprehensive number of determinants and biomarkers tested.

  2. T-helper-1 or T-helper-2 Dominance (Immunotypes 6 and 7)
    Includes the Cyrex Fluorescence Activated Cell Test (FACT™), a breakthrough proprietary process, is used to classify Th1/Th2 balance, based on the specific clusters of differentiation (CD markers) on the surface membranes of Th1 or Th2 cells, and NOT on the measurement of Th1/Th2-associated cytokine levels in the blood, commonly used by other laboratories.

  3. T-helper-17 Dominance (Immunotype 9) Includes the Cyrex FACT™ , a proprietary process based on direct measurement of the CD markers on the surface membranes of the cells, and NOT by measuring IL-17 levels in the blood.

    These industry-changing features result in a more accurate picture of T-helper cell status than currently available on the market.

  4. The most comprehensive immunophenotyping panel offered on the market, creating the broadest picture of immune status.